Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 18 of 18 publications.

La E, Singer D, Dubois de Gennes C, Graham J, Grace M, Poston S, Verelst F. Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination in US adults aged 60 years with cardiopulmonary disease. Poster to be given at the ISPOR 2025; May 15, 2025. Montreal, Canada.

Singer D, La E, Dubois de Gennes C, Graham J, Grace M, Biundo E, Poston S, Verelst F. Estimated public health impact of adjuvanted RSVPreF3 vaccination in US adults aged 18-49 years who are at increased risk for severe RSV disease. Poster to be given at the ISPOR 2025; May 15, 2025. Montreal, Canada.

Singer D, La E, Dubois de Gennes C, Graham J, Grace M, Biundo E, Poston S, Verelst F. Modeled public health impact of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years at increased risk for severe RSV disease in the United States over 5 years. Poster presented at the 13th International Respiratory Syncytial Virus (RSV) Symposium; March 12, 2025. Iguazu Falls, Brazil.

Verelst F, La E, Singer D, Graham J, Grace M, Biundo E, Poston S. Modelled public health impact of adjuvanted RSVPreF3 vaccination in adults aged 60 years and older in the United States over 5 years. Poster presented at the 13th International Respiratory Syncytial Virus (RSV) Symposium; March 12, 2025. Iguazu Falls, Brazil.

Shah HA, Jutlla G, Herrera-Restrepo O, Graham J, Grace M, Khan SA, Kuylen E, Begum S, Verelst F, Kocaata Z. Market and non-market productivity losses associated with invasive meningococcal disease in the USA. Pharmacoeconomics. 2025 Mar 12. doi: 10.1007/s40273-025-01477-0

Shah HA, Jutlla G, Herrera-Restrepo O, Graham J, Hicks KA, Carrico J, Grace M, Clements DE, Burman C, Sohn WY, Kuylen E, Begum S, Kocaata Z. Public health impact of introducing a pentavalent vaccine against invasive meningococcal disease in the United States. Pharmacoeconomics. 2025 Mar;43(3):311-29. doi: 10.1007/s40273-024-01439-y

Grace M, Wang K, Graham CN. Budget impact of injectafer (ferric carboxymaltose injection) for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity on a third-party US payer. Poster presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024; October 14, 2024. Las Vegas, NV.

Buck P, Graham J, Grace M, Myers E, Diaz-Decaro J. Public health impact of vaccination strategies in 16-to-40-year-old females for the prevention of CMV and congenital CMV in the United States. Poster presented at the European Congenital Cytomegalovirus Initiative (ECCI) 2024; October 9, 2024. Leiden, The Netherlands. Previously presented at the European Society for Paediatric Infectious Diseases (ESPID) 2024.

Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Cost effectiveness of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years with diabetes in the United States. Poster presented at the American Diabetes Association's 84th Scientific Sessions; June 21, 2024. Orlando, FL. [abstract] Diabetes. 2024 Jun; 73(Suppl 1):1045.

Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Cost-effectiveness of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years with cardiopulmonary diseases in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S137. doi: 10.1016/j.jval.2024.03.735

Buck P, Graham J, Grace M, Myers E, Diaz-Decaro J. The public health impact of vaccination strategies in 16-to-40-year-old females for the prevention of cytomegalovirus and congenital cytomegalovirus in the United States. Poster presented at the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 24, 2024. Copenhagen, Germany.

Shah HA, Herrera-Restrepo O, Jutlla G, Grace M, Graham J, Khan SA, Begum S, Kocaata K. Market and non-market productivity losses associated with invasive meningococcal disease (IMD) in the United States (US). Poster presented at the 42nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 20, 2024. Copenhagen, Denmark.

La E, Singer D, Graham J, Grace M, Molnar D. Modeled public health impact of increasing respiratory syncytial virus vaccination coverage among adults Aged ≥ 60 years in the United States. Poster presented at the 2024 Virtual Annual Conference on Vaccinology Research; May 8, 2024.

Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Modeled burden of RSV in adults aged 50-59 years with chronic cardiopulmonary diseases in the United States. Poster presented at the 8th ReSViNET Conference 2024; February 13, 2024. Mumbai, India.

Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Modeled impact of adjuvanted RSVPREF3 vaccination on RSV-related health outcomes in adults aged 50-59 years with cardiopulmonary diseases in the United States. Poster presented at the 8th ReSViNET Conference 2024; February 13, 2024. Mumbai, India.

Grace M, Costello J, Colosia A, Wolowacz S, Ghaswalla P, Panozzo CA, Moore P. Economic and HRQoL burden in adults with RSV: a systematic literature review. Poster presented at the Communicable Diseases & Immunisation Conference 2023; June 20, 2023. Perth, Australia. Previously presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW).

Grace M, Costello J, Colosia A, Wolowacz S, Panozzo CA, Ghaswalla P. Economic and health-related quality of life burden in adults with RSV: a systematic literature review and gap analysis. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.

Grace M, Colosia A, Wolowacz S, Panozzo C, Ghaswalla P. Economic burden of respiratory syncytial virus infection in adults: a systematic literature review. J Med Econ. 2023;26(1):742-59. doi: 10.1080/13696998.2023.2213125